Navigation Links
Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
Date:5/26/2009

Phase 1/2 Calcium Upregulation by Percutaneous Administration (CUPID) Data Highlight Safety Profile and Biological Effects of SERCA2a Enzyme Replacement

SAN DIEGO, May 26 /PRNewswire/ -- Celladon Corporation today announced that results from its genetically targeted enzyme replacement therapy for advanced heart failure, including Phase 1/2 data of MYDICAR(R) (AAV1/SERCA2a), will be presented by Krisztina M. Zsebo, PhD, President and CEO, Celladon Corporation and Howard Dittrich, MD, Cardiologist at University of California, San Diego School of Medicine, in a Scientific Symposium on Thursday, May 28 at the 2009 American Society of Gene Therapy Annual Meeting, San Diego Convention Center.

"A key underpinning of heart failure is the depletion of SERCA2a enzyme in heart muscle cells, which results in abnormal intracellular calcium cycling and poor contractility," said Zsebo. "Our research shows that recombinant adeno-associated viral vectors (AAV) are ideal for restoring SERCA2a enzyme production by means of cardiac muscle gene transfer. The path of investigation for MYDICAR(R) (AAV1/SERCA2a), from rodent studies to the ongoing Phase II clinical trial, has yielded valuable insights for the entire gene therapy field, dispelling many myths and revealing strategies to enhance vector uptake in humans with numerous applications."

While conventional drug therapies have improved survival of patients with congestive heart failure, the disease progresses relentlessly, resulting in more than 300,000 deaths each year, 6.5 million annual hospital days and an estimated $35 billion in direct and indirect healthcare expenditures. Recent advances in understanding the molecular basis of myocardial dysfunction, together with the evolution of safe and efficient gene transfer technology, have placed heart failure within reach of gene-based therapy. A Phase 1/2 clinical trial of dose escalation of MYDICAR administered directly to heart cells with minimally invasive cardiac catheterization is currently underway. This clinical study represents the first-in-human trial of enzyme replacement therapy in heart failure using AAV and has demonstrated acceptable safety and produced quantitative evidence of biological activity across a number of parameters important for assessing heart failure. Celladon is testing the hypotheses that restoring SERCA2a enzyme production will improve ventricular function in patients with advanced heart failure.

About Celladon

Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The company's products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium cycling and contractility in heart muscle cells. Celladon's first product candidate, MYDICAR, delivers the gene for the SERCA2a enzyme. MYDICAR is currently being tested in Phase 1 and 2 clinical trials. Celladon is also developing traditional small molecule activators of SERCA2a for the treatment of heart failure. To learn more about Celladon, visit Celladon's website at www.celladon.net.


'/>"/>
SOURCE Celladon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
2. Juvenile Diabetes Research Foundation to Honor Duane DeSisto of Insulet Corporation and Senator Edward M. Kennedy at 27th Annual Hearts & Heroes Gala
3. CEL-SCI Corporation Releases Letter to Shareholders
4. Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan
5. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
6. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
7. AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
8. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
9. CEL-SCI Corporation Releases Letter to Shareholders
10. Chemstar Corporation Offers Comprehensive Deep Cleaning Programs to Combat Salmonella, Listeria, and E. coli in Retail Supermarkets
11. Christie Cookie Recalls Certain Lots of Peanut Butter Cookie Dough Due to Expanded Recall by Peanut Corporation of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 ... addition of the "Global Musculoskeletal Partnering ... company profile to their offering. ... addition of the "Global Musculoskeletal Partnering ... company profile to their offering. ...
(Date:2/5/2016)... Dehaier Medical Systems Ltd. (Nasdaq: ... develops, markets and sells medical devices and wearable ... and international markets, today announced its corporate ... the Company,s resources to develop its mobile health ... focus more on its major businesses. As of ...
(Date:2/5/2016)... Site Profile: --> ... The Speech Recognition People, announced their latest primary healthcare case study ... reduce turnaround times and to save the practice money. ... 2013 Challenge: --> ,- Wirral CCG ,- ... Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... ... Love is in the air at King Kullen! The local grocer is ... staple for Valentine’s Day is a must-have, and can be picked up with all ... are long-stem roses available, but also other flower bouquets, elegantly wrapped and ready to ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... , ... Stuart Bentkover, MD, FACS is thrilled to announce the ... effective tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts to ... has been approved by the Food and Drug Administration (FDA) as a safe and ...
Breaking Medicine News(10 mins):